Actinogen Medical completed patient enrollment for its XanaCIDD Phase 2a trial with 167 participants.
The trial assesses Xanamem's efficacy in treating cognitive impairment in major depressive disorder patients by reducing brain cortisol levels without affecting normal stress response.
Results are due in the early third quarter, focusing on improving cognitive functions beyond traditional antidepressants.
Claim Now
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments